⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis (S31.003)

Gabriel Pardo Stephen L. Hauser Amit Bar‐Or Ralf Gold Xavier Montalbán Jeffrey A. Cohen Derrick Robertson Carrie M. Hersh Robert T. Naismith Kumaran Deiva Alit Bhatt Haoyi Fu Ibolya Boer Sven G. Meuth Anne H. Cross Jutta Gärtner Ludwig Kappos

View Full Paper

Ask AI

Bookmark

Share

Abstract

To assess ofatumumab's longer-term efficacy for up to 6 years in people with recently diagnosed treatment-naive (RDTN) relapsing multiple sclerosis (RMS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pardo et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcc5b6db643587677352 https://doi.org/10.1212/wnl.0000000000206274

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years (P9-6.010)2024 · 5 citations
2Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosiscohort · 2025 · 7 citations
3Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extensioncohort · 2023 · 56 citations
4Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosisRCT · 2014 · 278 citations
5Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosisRCT · 2018 · 219 citations